OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Pistollato, M.

Research Paper
August 2015

Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the future prices and market shares of a drug? Understanding the answers to these questions can be crucial when conducting cost-effectiveness analyses i.e. when studying if it is desirable to publicly fund reimburse a new drug. This paper models and studies the price of a new drug along its life-cycle, from launch to discontinuation, to understand how the price of the drug evolves and to help inform cost-effectiveness evaluations.

O'Neill, P. and Sussex, J.

Consulting Report
May 2015

The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has been commissioned by LIF, the trade association of the pharmaceutical industry in Sweden, to reanalyse the international comparison of medicines uptake from the Swedish perspective; and the results are available here and on LIF’s website.

Cook, J.P.

Seminar Briefing
April 2014

Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available at launch. As the author points out, oncology drugs in particular often follow the path of incremental innovation, proceeding in steps towards realising their full potential in treatment -- and even cure.

Mestre-Ferrandiz, J., Deverka, P., Pistollato, M. and Rosenberg, E.

Occasional Paper
April 2014

The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis. A literature review helped elucidate concepts and define focus. The authors then conducted semi-structured interviews with an international sample of 19 senior pharmaceutical executives in various positions in the five companies: R&D, outcomes research, medical affairs, and pricing and reimbursement.

O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J.

Research Paper
January 2014

The Pharmaceutical Price Regulation Scheme (PPRS) 2014 Heads of Agreement, announced on 6 November 2013, outlines the terms of the five-year deal between the pharmaceuctical industry and the government in the UK. For the first time, the PPRS caps future growth in the NHS's branded medicines bill, between 2014 and 2018.

Mattison, N. ed.

Monograph
July 2013

Based on OHE’s 50th anniversary conference, this publication captures the views of thought leaders from around the world about the scientific and economic climate for drug development by 2022.

Four major themes stood out in the conference discussions, as reported in this publication.

1. Health care will be radically transformed as “precision” medicine plugs into the specific  genetic makeup of both patients and diseases, and is paired with increasingly powerful and convenient diagnostics.

O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J.

Research Paper
April 2013

Medicines account for less than 10% of total NHS expenditure in the UK. Because spending on medicines is easy to separate out, however, this sector continues to come under particular scrutiny in efforts to manage costs. Forecasting spending on medicines can be useful in planning NHS resource allocation. Simple extrapolations of past trends in medicines expenditure, however, are insufficient because they cannot account for shifts in the mix of medicines available on the market or the appearance of generics.

O’Neill, P., Puig-Peiro, R., Mestre-Ferrandiz, J. and Sussex, J.

Consulting Report
October 2012

Since 1996, in its yearly PPRS Report to Parliament, the Department of Health in England has published international price comparisons of branded medicines used in the primary care setting. OHE Consulting uses the same methodology in this report to update comparisons through 2011.

Pages